Corbus announced that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM CDT by Dr. Jian Zhang, Fudan University Shanghai Cancer Center. https://bit.ly/4aEsN4u #ASCO24
Corbus Pharmaceuticals’ Post
More Relevant Posts
-
Very excited to be at the Society for Immunotherapy of Cancer (SITC) annual meeting to present new preclinical data for casdozokitug, a first-in-class IL-27 antibody. The poster highlights the IFN signaling-like properties of IL-27 and importantly describes biomarkers that may be useful for evaluating cancer patient treatment with casdozokitug. View the poster: https://bit.ly/3Mti9UU #SITC2023
To view or add a comment, sign in
-
-
A recently published study by Merck KGaA, Darmstadt, Germany, EMD Serono, Inc., Christian-Albrechts-Universität zu Kiel, and Technische Universität Darmstadt investigates bispecific NK cell-engaging antibodies (NKCEs) for cancer immunotherapy, focusing on the impact of antibody architecture on their efficacy. ✅ It highlights the importance of design, valency, and NKp30 epitope recognition in influencing NKCE characteristics. ✅ The research emphasizes the benefits of Fc domains for prolonged half-life and demonstrates that the tested NKCEs exhibit IgG-like pharmacokinetic profiles, indicating their clinical potential in cancer treatment. ✅ For simultaneous binding experiments as well as kinetic measurements the Octet®️ BLI technology was used. Read the study here: https://ow.ly/mzfO50RE5fG #AntibodyEngineering #ProteinEngineering #Antibodies #DrugDevelopment #EpitopeMapping #OctetBLI
To view or add a comment, sign in
-
-
In November 2023, our CMO, Dr. Qasim Iftikhar Ahmad, participated in Drug Discovery World's Turning Science into Business Summit, focusing on 'cancer research opportunities and advances' and 'cutting-edge concepts and tools in cancer drug discovery'. During his presentation, Dr. Ahmad delved into IO Biotech's novel immunotherapy approach and its lead investigational therapeutic cancer vaccine candidate, IO102-IO103, with a dual mechanism of action designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment, which is currently being evaluated in a pivotal Phase 3 study for the first line treatment of patients with advanced #melanoma. Read more on page 10 in Drug Discovery World's Winter 2023/2024 issue here: bit.ly/3S6FA8A.
To view or add a comment, sign in
-
Extensive Stage Small Cell Lung Cancer Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic: JERSEY CITY, N.J., Dec. 13, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Extensive Stage Small Cell Lung Cancer Market By Products (Commercial, Clinical), Market Outlook and Industry Analysis 2031" According to...
To view or add a comment, sign in
-
[ 🔔 📢 NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?] The Cancer Drug Development Forum (CDDF) is delighted to announce that the White Paper has been developed following its ‘Histology Independent Drug Development – Is This the Future for Cancer Drugs?’ workshop, which took place on 14-15th November 2022, in Amsterdam. The hybrid meeting was set up to explore the current landscape of histology independent drug development, review the current regulatory landscape and propose recommendations for improving the conduct of future trials. 🔔📑 Read the full article published in Cancer Treatment Reviews here: https://lnkd.in/ebgtynQA #Cancer #oncologytrials #HistologyIndependent #Tumour #Biomarkers #DataSharing
To view or add a comment, sign in
-
-
During my college and med school years, the #HumanGenomeProject was in full swing. As a self-proclaimed nerd, I was thrilled by the potential of sequencing the human genome. Last week, I felt that same excitement at an internal meeting discussing the Cell Surfaceome. This initiative holds immense promise for oncology drug development, particularly in the use of radioligands, antibody-drug conjugates (ADCs), and other innovative therapies. For those interested in learning more, this article is a great place to start: Elucidating the Cell Surfaceome to Accelerate Oncology Drug Development. #RLT #AACR #DrugDevelopmemt #Oncology #Cancer #Surfaceome Novartis https://lnkd.in/gvaUeDst
To view or add a comment, sign in
-
A great initiative. Understanding tumor biology is at the heart of precision medicine.
NCI has launched a large #PrecisionMedicine cancer initiative, known as Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), to test the effectiveness of treating adults and children with new drug combinations that target specific tumor alterations. Dive in for the details about this initiative that is the largest of its kind to test combinations of cancer drugs guided by #TumorBiology. http://spr.ly/6046RpoGn #NCIHighlights2023 #BestOf2023
ComboMATCH will test new combinations of cancer drugs
To view or add a comment, sign in
-
The development of antibody drug conjugates (ADCs) presents a promising alternative to traditional chemotherapy for cancer treatment. By targeting cancer cells specifically, these drugs offer the potential to reduce severe side effects and improve effectiveness. Though widespread adoption may take time, ongoing advancements suggest a future where ADCs play a central role in cancer care.</div><div class="read-more"><a href="" class="more-link">Continue reading</a>https://lnkd.in/gu9SsF4U
The endgame for chemo?
To view or add a comment, sign in
-
Harnessing the power of Boron-10, drugs like Boronophenylalanine (BPA) are revolutionizing cancer treatment. Unlike other radiopharmaceuticals, BPA used in Boron Neutron Capture Therapy (BNCT) targets cancer cells with remarkable precision and 🌟 activated only🌟 when the patient is exposed to a beam of low-energy (epithermal) neutrons. The neutrons interact with the boron-10 atoms, producing high-energy alpha particles and lithium nuclei, effectively destroying cancer cells while sparing surrounding healthy tissue. This precise targeting and localized radiation damage make BNCT a promising, more effective, and less invasive treatment. Stay tuned for updates on how TAE Life Sciences and our novel Boron-10 drugs and BNCT are transforming oncology! 🧬 #CancerResearch #BNCT #Boron10 #OncologyInnovation #MedicalBreakthroughs
To view or add a comment, sign in
-
🎉 Groundbreaking News in AML Research! 🎉 Exscientia plc is taking a giant leap in acute myeloid leukaemia (#aml ) treatment with the launch of the EXCYTE-2 study! 🧬🔍 👩🔬 What's Happening: EXCYTE-2 Study Kickoff: Focusing on first-line AML patients, with eyes set on expanding to second-line patients facing critical unmet medical needs. 🩸🔬 Precision Medicine Meets AI: Leveraging Exscientia’s cloud-based AI to analyze primary blood or bone marrow samples, aiming to match patients with the most effective treatments. 🌐🧠 Supporting LSD1 Inhibitor Development: Through evaluating the activity of EXS74539, Exscientia’s promising LSD1 inhibitor, this study could pave the way for targeted clinical trials. 💊🎯 🚀 Why It Matters: Innovation at Its Core: EXCYTE-2 is set to build on the success of previous precision medicine studies, like EXALT-1 and EXCYTE-1, pushing the boundaries of AI in cancer treatment. 🌟 Hope for AML Patients: With the potential to change clinical practices, this study offers a beacon of hope for those battling AML, aiming for more personalized and effective treatment strategies. ❤️🙏 🔬 Looking Forward: As Exscientia continues to harness the power of AI in developing groundbreaking therapies, the EXCYTE-2 study represents a crucial step forward in the fight against AML. 🥼📈 Stay tuned for how this journey unfolds, potentially setting a new standard in cancer care. 📚💖 Join us in cheering on this monumental progress in AML research and precision medicine! 🎗️👏 #AML #EXCYTE2 #PrecisionMedicine #Exscientia #AIInHealthcare #FightCancer #InnovativeResearch #HopeForAML 🎉🔬🧬
Really excited to announce that Exscientia has initiated the EXCYTE-2 clinical study to evaluate the precision medicine platform in AML cancer patients, which will also enhance the ongoing development of the LSD1 inhibitor (EXS74539). $EXAI Exscientia https://lnkd.in/euHmenhh This comes off the back of the successful EXALT-1 proof-of-principle trial, and the ongoing EXCYTE-1 trial in ovarian cancer. It also follows on from recent academic work showing that this technology can be applied to AML in the DARTT-1 study. True precision medicine & clinical translation involves being able to determine exactly which patients will benefit from a drug as you design the drug. Patients . . . not cell lines!
To view or add a comment, sign in
-